HAE Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 13.2% compared to Haemonetics Corp.'s net margin of 12.68%. Haemonetics Corp.'s return on equity of 20.07% beat Boston Scientific Corp.'s return on equity of 12.55%.

Haemonetics Corp. has a consensus price target of $88.00, signalling upside risk potential of 43.81%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Haemonetics Corp. has higher upside potential than Boston Scientific Corp., analysts believe Haemonetics Corp. is more attractive than Boston Scientific Corp..

Haemonetics Corp. has a beta of 0.283, which suggesting that the stock is 71.675% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Haemonetics Corp. quarterly revenues are $339M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Haemonetics Corp.'s net income of $44.7M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 16.81x while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.23x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

DexCom, Inc. has a net margin of 13.2% compared to Haemonetics Corp.'s net margin of 21.22%. Haemonetics Corp.'s return on equity of 20.07% beat DexCom, Inc.'s return on equity of 33.68%.

Haemonetics Corp. has a consensus price target of $88.00, signalling upside risk potential of 43.81%. On the other hand DexCom, Inc. has an analysts' consensus of $85.46 which suggests that it could grow by 16.94%. Given that Haemonetics Corp. has higher upside potential than DexCom, Inc., analysts believe Haemonetics Corp. is more attractive than DexCom, Inc..

Haemonetics Corp. has a beta of 0.283, which suggesting that the stock is 71.675% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.074%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.

Haemonetics Corp. quarterly revenues are $339M, which are smaller than DexCom, Inc. quarterly revenues of $1.3B. Haemonetics Corp.'s net income of $44.7M is lower than DexCom, Inc.'s net income of $267.3M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 16.81x while DexCom, Inc.'s PE ratio is 34.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.23x versus 6.36x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 13.2% compared to Haemonetics Corp.'s net margin of 14.46%. Haemonetics Corp.'s return on equity of 20.07% beat Masimo Corp.'s return on equity of -19.18%.

Haemonetics Corp. has a consensus price target of $88.00, signalling upside risk potential of 43.81%. On the other hand Masimo Corp. has an analysts' consensus of $178.60 which suggests that it could grow by 2%. Given that Haemonetics Corp. has higher upside potential than Masimo Corp., analysts believe Haemonetics Corp. is more attractive than Masimo Corp..

Haemonetics Corp. has a beta of 0.283, which suggesting that the stock is 71.675% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.165%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Haemonetics Corp. quarterly revenues are $339M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Haemonetics Corp.'s net income of $44.7M is lower than Masimo Corp.'s net income of $53.7M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 16.81x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.23x versus 5.53x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 13.2% compared to Haemonetics Corp.'s net margin of 11.84%. Haemonetics Corp.'s return on equity of 20.07% beat Stryker Corp.'s return on equity of 15.17%.

Haemonetics Corp. has a consensus price target of $88.00, signalling upside risk potential of 43.81%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 11.62%. Given that Haemonetics Corp. has higher upside potential than Stryker Corp., analysts believe Haemonetics Corp. is more attractive than Stryker Corp..

Haemonetics Corp. has a beta of 0.283, which suggesting that the stock is 71.675% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.89% to investors and pays a quarterly dividend of $0.88 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics Corp. quarterly revenues are $339M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Haemonetics Corp.'s net income of $44.7M is lower than Stryker Corp.'s net income of $849M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 16.81x while Stryker Corp.'s PE ratio is 45.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.23x versus 5.85x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.